alfexe/iStock via Getty Images Akero Therapeutics, Inc. (NASDAQ:AKRO) has been able to report positive results from its phase 2b HARMONY study, which used its drug efruxifermin [EFX] for the treatment of patients with pre-cirrhotic MASH or Metabolic dysfunction-associated steatohepatitis with stage 2 or 3 fibrosis. The significance of this is that it is already in the process of testing out this drug in a phase 3 program known as SYNCHRONY. Patients have already been dosed in the first two phase 3 studi ...

      50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%) 50mg (36%, p<0.01) and 28mg (31%, p<0.01) EFX groups demonstrated ≥2 stage improvement in fibrosis without worsening of MASH, more than 10-fold the placebo rate (3%) EFX-treated patients experienced statistically significant improvements on nearly all histological endpoints by ITT analysis as well as the primary analysis ...

AKRO股票分析 - AKRO上周收盘价为$26.99，过去四周上涨了28.7%[1] - 分析师的平均目标价为$42.88，显示了58.9%的上涨潜力[1] - AKRO目前的Zacks排名为2（买入），这是股票短期潜在上涨的更具有说服力的指标之一[11]

Akero Therapeutics, Inc.投资者会议 - Akero Therapeutics, Inc.将于3月4日举行投资者会议，分享HARMONY研究96周治疗结果[1] - 公司提到了未来展望性声明，包括SYNCHRONY Phase 3计划和HARMONY研究96周结果的预期时间[10] HARMONY研究 - HARMONY研究是一项双盲、安慰剂对照的2b期研究，评估EFX在患有MASH的患者中的疗效[3] EFX治疗效果 - EFX治疗在24周后显示出积极结果，对肝纤维化和MASH的改善效果显著[4] - EFX是Akero的主力候选药物，旨在治疗MASH，具有改善肝脂肪、逆转纤维化、增加胰岛素敏感性和改善血脂的作用[5] MASH疾病 - MASH是一种严重的MASLD形式，预计到2030年将影响超过2500万美国人，目前尚无批准的治疗方法[6] 公司背景 - Akero Therapeutics是一家临床阶段公司，致力于为患有严重代谢疾病的患者开发变革性治疗方法，总部位于南旧金山[8] - Akero目前正在进行两项进行中的3期临床试验，评估EFX在MASH患者中的疗效[9]

公司业绩 - Akero Therapeutics, Inc.（NASDAQ:AKRO）报告了2023年第四季度和全年财务业绩[1] - 公司的研发费用在2023年增加，主要用于支持正在进行的临床研究和潜在的市场申请[15] - Akero相信其现金储备将足以支持其当前的运营计划直至2026年[13] 产品研发 - 公司正在进行两项第三阶段SYNCHRONY研究，评估EFX在治疗患有早期肝硬化MASH的患者中的疗效[2] - EFX是公司的主力产品候选药物，旨在减少肝脂肪和炎症，逆转纤维化，增加胰岛素敏感性和改善脂质[18] 市场前景 - MASH是一种严重的MASLD形式，预计到2030年将影响超过2500万美国人[19]

33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38944 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-5266573 (State or Other Jurisdi ...

财务业绩 - Akero Therapeutics报告2023年第四季度和全年财务业绩，截至2023年12月31日，现金、现金等价物和短期可市场证券总额为550,010美元[20] - 研发费用在2023年12月31日三个月和十二个月期间分别为53.4百万美元和141.8百万美元，较2022年同期分别增加了35.1百万美元和56.5百万美元[11] 研究结果 - EFX在SYMMETRY研究中观察到28mg和50mg治疗组MASH解决率分别为67%和60%，显著高于安慰剂组的26%[7]

AKRO股价走势 - Akero Therapeutics, Inc. (AKRO) 最近股价下跌5.9%[1] - 形成了锤子图案，可能意味着股票找到支撑，可能会出现趋势反转[1] - 锤子图案是蜡烛图中的一种价格模式，通常在下跌趋势中出现，表明可能见底[3] - 锤子蜡烛可以出现在任何时间段，被短期和长期投资者使用[5] AKRO基本面分析 - AKRO的盈利预期修订呈上升趋势，这是基本面上的多头指标[7] - 过去30天，AKRO今年的每股收益预期已增加0.1%，分析师普遍认为公司将报告更好的盈利[8] - AKRO目前拥有Zacks Rank 2 (买入)，通常表现优于市场[9]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Akero Therapeutics, Inc. (AKRO) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Akero Therapeutics, Inc. is one of 1074 individual stocks in the Medical sector. Collectively, these companies sit at #10 in the Z ...

The shares of Akero Therapeutics Inc (NASDAQ:AKRO) have been steadily climbing from their November lows following a steep early October bear gap, though pressure seems to have appeared at the $25 level. Plus, if past is precedent, the biotech name could be headed for a short-term dip. AKRO's recent rally took it within one standard deviation of its 80-day moving average, a trendline with historically bearish implications. According to Schaeffer's Senior Quantitative Analyst Rocky White, the equity stock has ...